Plenary
Lecture
Liposomes in Tuberculosis Diagnosis
Professor P. S. Bisen
Co-authors: Anish Zachariya, R. P. Tiwari
Bisen Biotech & Biopharma Pvt. Ltd.
M-7 Laxmipuram, Transport Nagar
Gwalior, India
E-mail:
psbisen@bisenbiotech.com
Abstract: The tuberculosis
which is responsible for several
millions of deaths in the tropical
world can be addressed very
effectively if diagnosed at an
early stage. The diagnosis of
tuberculosis continues to pose
serious problems, mainly because
of difficulties in differentiating
between patients with active
tuberculosis and those with healed
lesions, normal mycobacterium
boris BCG (Bacillus Calmette
Guerin) vaccinated individuals,
and unvaccinated Manteux
positives. The present study
explores the potential utility of
liposomes in serodiagnosis
(antibody as well as antigen
based) of tuberculosis in humans.
A cock tail of Glycolipid antigens
from Mycobacterium tuberculosis
H37 Rv were extracted purified and
characterized by analytical
techniques. The glycolipid
antigens were either inserted in
to liposomes or injected into
rabbits for raising specific
polyclonal antibodies. Affinity
purified rabbit anti-glycolipid
antibodies (IgG) were coupled to
liposome particles (0.2-0.4 µm) in
presence of
1-Ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride and
N-hydroxysuccinamide.
Antibody-conjugated liposomes were
employed by agglutination test for
detection specific antigens. A
visible dark blue agglutination
within 4 minutes is seen if M.
tuberculosis antigens are present
in the diagnostic specimen.
Hundreds of sera samples from
subjects with pulmonary
tuberculosis and extra-pulmonary
tuberculosis were screened for
detection of M. tuberculosis
specific antigens as well as
antibodies by liposomal
agglutination tests and the
results were compared with
conventional tests and those
commercially available diagnostic
tests. The liposomal agglutination
tests were shown to be effective
in diagnosing patients with active
tuberculosis with high sensitivity
and specificity and the prototype
kits developed were compared with
those commercially available kits
in terms not only of sensitivity
and specificity but also of
rapidity and cost effectiveness.
The technology has been evaluated
in well known research
institutions, hospitals, medical
colleges and pathology centers
among various parts of our country
for it’s sensitivity and
specificity. The kit worked
consistently well at every
Institute / hospital where
validation studies had taken
place. The sensitivity,
specificity, simplicity, cost
effective ness have been
established with clarity. The
liposomal agglutination tests
demands neither technical
expertise nor expensive equipment
for reading the result. The result
can be read with naked eye and
without any ambiguity with in 5
minutes. Another innovative
feature of the technology
developed is it’s longevity even
at ambient temperature. The
liposomal kits do not require
refrigeration either during
transport or during storage. Thus
the liposome based diagnostic
technology is superior to existing
ones, cost effective and is first
of it’s kind in the world.
Brief Biography of the Speaker:
Worked at University of Illinois
at Chicago and at University of
California, Davis, U.S.A. during
1986-87, Marie Curie Fellow of
European Union in 1994,1996 and
worked at Lancaster University,
Lancaster, UK, DAAD Fellow in Bonn
University, Germany in 1997 and
1998, UNDP Fellow at Biological
Research Centre, Hungarian Academy
of Sciences, Szeged, (1978-1979)
and 1982 and WHO Fellow at the
Institute of Microbiology,
Czechoslovakia Academy of
Sciences, Praha, Czecholovakia in
1983. He has served as Professor
of Microbiology and Biotechnology,
Barkatullah University, Bhopal
(1985 - 2001), Vice-Chancellor
Jiwaji University, Gwalior (1994
to 1996), Dean, Academic, Planning
and Development, Bundelkhand
University, JHANSI, (U.P.) June
2004 to July 2005. Director,
Madhav Institute of Technology and
Science, Gwalior, (2001 - June
2004). Since 2007, Professor Bisen
is an Honorary Professor of
Biotechnology at Jiwaji
University, Gwalior, India.
Presently, Professor Bisen is the
Chairman of Bisen Biotech and
Biopharma (P) Ltd. - a private
equity venture which focuses on
diagnostic solutions for
widespread diseases. Professor
Bisen is also the Chairman of the
Vikrant Group, which focuses on
advancing technical education
through technical institutes at
Gwalior and Indore, India.
|